Key Highlights

• Andy Reding’s base compensation is $500,000 per year, with a target bonus equal to 70% of that amount.

• The agreement provides a cash sign‑on of $100,000 and reimburses $2,500 for legal expenses.

• An RSU award representing 130,000 shares will vest equally over three years.

• Severance provisions include up to 24 months of salary continuation if termination occurs during a change‑of‑control window.

Inogen Inc. (NASDAQ: INGN) reported that its board has selected Andy Reding to serve as executive vice president and chief operating officer, with the assignment slated to begin in July 2026. The decision follows a board action taken earlier in June 2026 and was communicated through a company press release in early July.

Leadership Selection

Reding, a seasoned executive in medical‑device commercialization, will oversee day‑to‑day operations. His background includes leading the commercial function at Viant Medical from late 2020 through early 2026, as well as senior positions at Hillrom Respiratory Health and Trumpf Medical Systems.

Compensation Overview

The employment agreement sets a $500,000 base salary and a target annual performance bonus equal to 70% of that salary. A cash sign‑on payment of $100,000 is payable at the start date, and the company will reimburse $2,500 for legal fees incurred in connection with the agreement.

Equity Incentives

Reding will receive restricted stock units representing 130,000 shares of Inogen common stock. The RSUs will vest in equal thirds over a three‑year period, with one‑third becoming unrestricted each year. The award is issued as an independent inducement and qualifies for an exemption from Nasdaq shareholder‑approval requirements under Rule 5635.

Severance Provisions

If Reding’s employment ends without cause outside a defined change‑of‑control period, he will receive twelve months of continued base salary. Should termination occur within the twelve‑month window surrounding a change of control, salary continuation extends to twenty‑four months. Severance payments are conditional on his execution of a release of claims and adherence to post‑employment covenants.

Regulatory Filings

Inogen filed its standard indemnification agreement with the SEC on November 27, 2013. The filing provides customary protection for Reding against personal liability arising from his executive duties. The compensation structure is designed to avoid triggering the excise tax under Section 4999 of the Internal Revenue Code, thereby maintaining tax‑efficient benefits for the executive.

Market Implications

The selection underscores Inogen’s emphasis on bolstering operational leadership as the company expands its portfolio of portable oxygen concentrators. Stakeholders will monitor how Reding’s commercial expertise influences revenue growth and whether the compensation framework aligns with shareholder expectations for executive remuneration.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.